Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin

Diagnostic Tests for Agents of Community-Acquired Pneumonia

(2011) John G. Bartlett   CLINICAL INFECTIOUS DISEASES

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) Donald E. Low et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) T. M. File et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

(2010) Thomas M. File et al.   CLINICAL INFECTIOUS DISEASES

Burden of Community-Acquired Pneumonia in North American Adults

(2010) Thomas M. File et al.   POSTGRADUATE MEDICINE

Community-Acquired Pneumonia: The U.S. Perspective

(2009) Michael Niederman   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia

(2008) Peter E. Pertel et al.   CLINICAL INFECTIOUS DISEASES